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Epinephrine and potassium homeostasis. The effect of epinephrine on
potassium metabolism was examined in six subjects. Each subject
participated in four studies as follows: (1) potassium chloride infusion
(0.75 mEq/kg, i.v.) given over 2 hours, (2) epinephrine (0.05 g/kgmin)
plus potassium chloride, (3) propranolol (1.43 g/kgmin) plus epineph-
rine plus potassium chloride, and (4) propranolol plus potassium
chloride. The epinephrine infusion with potassium chloride led to a
marked improvement in potassium tolerance, which was due to a
greater than twofold increase in the extrarenal disposal of potassium (P
<0.001). The enhancing effect of epinephrine on extrarenal potassium
uptake was completely reversed with the beta-blocking agent proprano-
lol. When propranolol alone was infused with potassium chloride, a
significant decrease in the extrarenal disposal of potassium was ob-
served. When potassium chloride was infused alone, 47% of the
administered potassium load was excreted in the urine. Epinephrine
infusion with potassium chloride markedly inhibited the urinary excre-
tion of potassium (UKV) to rates that were actually below the basal
potassium excretion rate (P <0.001). Propranolol almost completely
reversed this effect of epinephrine on UKV, and when propranolol was
infused alone, an enhancement in UKV (P < 0.005) was observed.
Insulin adds only a minor contribution to the enhancing effect of
epinephrine on extrarenal potassium disposal and does not contribute at
all to the inhibitory effect of epinephrine on renal potassium excretion.
These results demonstrate that epinephrine ameliorates the rise in
plasma potassium concentration following potassium chloride infusion.
Because none of the infused potassium was excreted during the 4-hour
study period, the improvement in potassium tolerance must result from
an enhancement in extrarenal potassium disposal. The ability of pro-
pranolol to reverse both the extrarenal and renal effects indicates that
the action of epinephrine is mediated via stimulation of the beta
receptor.
Epinéphrine et homéostasie du potassium. L'effet de l'épinéphrine sur
le métabolisme du potassium a etC Ctudié chez six sujets. Chaque suet a
participé a quatre etudes de Ia facon suivante: (1) perfusion de chlorure
de potassium (0,75 mEq/kg, i.v.) administrC en 2 heures, (2) CpinCphrine
(0,05 g/kg.min) plus chiorure de potassium, (3) propranolol (1,43 g/
kgmin) plus epinephrine plus chlorure de potassium, et (4) propranolol
plus chlorure de potassium. La perfusion d'Cpinephrine avec du chlor-
ure de potassium determine une augmentation importante de Ia tolCr-
ance au potassium, laquelle est due a une augmentation de plus du
double de Ia disposition extra-rCnale du potassium (P < 0,001). L'effet
d'augmentation par l'Cpinephrine de Ia captation extra-rCnale du potas-
sium a etC complCtement aboli par Ic beta bloquant propranolol, Quand
Ic propranolol seul a etC perfuse avec du chlorure de potassium, une
diminution significative de la disposition extra-rCnale de potassium a etC
observée, Quand le chlorure de potassium est perfuse seul, 47% de la
charge administrée sont excretes dans les urines. La perfusion d'Cpi-
nCphrine avec le chlorure de potassium a abaissC de facon importante
UKV a des debits infCrieurs aux valeurs basales (P < 0,00 1). Le
propranolol abolit presque completement cet effet de l'CpinCphrine sur
UKV et quand le propranolol est perfuse seul une augmentation de UKV
(P < 0,005) apparait. L'insuline n'apporte qu'une faible contribution a
l'effet d'augmentation par l'CpinCphrine de la disposition extra-rCnale
du potassium et ne contribue pas du tout a l'effet inhibiteur de
l'epinCphrine sur l'excrCtion rCnale de potassium. Ces rCsultats demon-
trent que l'epinephrine minimise l'Clévation de Ia concentration plasma-
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tique de potassium consecutive a une perfusion de chlorure de potassi-
um. Du fait que le potassium perfuse n'est pas excrétC pendant les 4
heures de l'Ctude il est prouvC que l'amélioration de Ia tolerance au
potassium est Ia consequence d'une augmentation de sa disposition
extra-renale. La capacitC qu'a le propranolol d'abolir a Ia fois l'effet
renal et l'effet extra-renal indique que cette action de l'Cpinephrine a
pour mCdiateur Ia stimulation des rCcepteurs beta.
Previous studies from our laboratory have shown that extra-
renal tissues play an important role in acute potassium toler-
ance, with extrarenal mechanisms accounting for the disposal
of approximately 50% of an acutely administered potassium
load [1, 2]. Both insulin [1] and adrenal hormones [3, 4] appear
to play key roles in this extrarenal potassium tolerance. Follow-
ing adrenalectomy, animals become hyperkalemic and demon-
strate a defect in both renal potassium excretion [5] and
extrarenal cellular uptake of potassium [3]. Although the renal
defect is reversible with exogenous mineralocorticoid adminis-
tration [3], in recent studies we have been unable to totally
correct the extrarenal defect in adrenalectomized rats with
aldosterone replacement alone. These results suggest that adre-
nal medullary hormones, particularly epinephrine, might also
play a role in maintaining extrarenal potassium tolerance.
D'Silva was the first to suggest that epinephrine might play a
role in potassium homeostasis [6]. He found that an i.v. infusion
of epinephrine into anesthetized cats resulted in an initial,
transient rise in plasma potassium followed by a prolonged
decline of approximately 1 mEq/liter. Similar results have been
reported by Todd et al [7, 8] in anesthetized dogs, and these
authors further demonstrated that the hypokalemic effect of
epinephrine could be prevented with the beta-blocking agent
propranolol. More recently, Lum and Lockwood [9, 10] have
examined the effect of epinephrine during the infusion of
pharmacologic doses of potassium into anesthetized cats. They
found that epinephnne ameliorated the rise in plasma potassium
concentration and reduced the incidence of hyperkalemia-
induced cardiac toxicity.
Little is known, however, about the effect of epinephrine on
potassium tolerance in man or the effect of epinephrine on renal
potassium handling. Recently, Rosa et al reported an improve-
ment in potassium tolerance with epinephrine and an impair-
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ment with propranolol in human subjects [11]. These investiga-
tors used very low doses of epinephrine. At higher rates of
epinephrine infusion, which produce plasma levels of epineph-
rine similar to that found during stress in man [16], insulin
secretion is stimulated due to the resultant hyperglycemia.
What role an increase in plasma insulin concentration following
epinephrine-induced hyperglycemia might play in the enhanced
potassium tolerance has not been examined. In many of the
previous animal studies in which potassium was infused [9, 101,
pharmacologic doses were administered, and this resulted in
increases in the plasma potassium concentration of 5 to 8 mEq/
liter above baseline. Therefore, the present study was undertak-
en (1) to examine the effect of epinephrine on a physiologic
increment in plasma potassium concentration, (2) to define the
renal as well as the extrarenal effects of epinephrine on acute
potassium tolerance, (3) to determine whether the protective
effect of epinephrine is exerted via beta or alpha receptors, (4)
to define the contribution of insulin to the enhancement in
potassium tolerance following epinephrine administration, and
(5) to determine whether a physiologic increment in potassium
concentration is capable of stimulating epinephrine release.
Methods
Subjects. Six healthy volunteers, ranging in age from 18 to 22
years and in ideal body weight from 97 to 118%, were studied.
There were five males and one female. No subject had any
significant past medical illness, none were taking any medica-
tions, and all were consuming a diet containing at least 200 g of
carbohydrate per day for 3 days prior to study. Informed,
written voluntary consent was obtained from each subject prior
to his participation in the study.
Experimental protocol. All studies were performed in the
postabsorptive state at 8 A.M. following a 12-hour overnight
fast, with subjects remaining recumbent during the study except
when voiding. Prior to study, polyethylene catheters were
inserted under local xylocaine anesthesia into an antecubital
vein for blood sampling and into a femoral vein for the infusion
of all test substances. Subjects were given a water load (15 ml!
kg) followed by enough deionized water orally to ensure voiding
every 30 mm. Following the collection of three baseline urine
samples, the infusion of test substances was begun. Each
subject participated in four studies performed in randomized
order and thereby served as his own control. In addition, three
subjects served as time controls and were followed for 6 hours
without receiving a test substance.
In the first study, potassium chloride was infused via a
constant infusion pump (model 975, Harvard Apparatus, Millis,
Massachusetts) at a rate designed to deliver 0.75 mEq of
potassium per kilogram of body weight over 2 hours. The
potassium chloride was dissolved in half-normal saline solution
and infused at the rate of 0.74 mllmin. The study was continued
for an additional 2 hours after stopping the potassium infusion.
In the second study, subjects received the same potassium
chloride infusion as in study one. In addition, a constant
infusion of epinephrine chloride (adrenalin chloride solution
1:1000, Parke-Davis and Co., Detroit, Michigan) at the rate of
0.05 ig!kgmin was started 30 mm prior to beginning the
potassium infusion and was continued throughout the 4-hour
study period. We have previously shown that this rate of
epinephrine administration produces levels similar to those
found during stress in man [12]. The epinephrine was dissolved
in half-normal saline and was administered at the rate of 0.27
ml!min. In the third study, potassium chloride and epinephrine
were administered as above. In addition, a constant infusion of
propranolol hydrochloride (Inderal, Ayerst Laboratories, Inc.,
New York City) given at the rate of 1.43 p.glkglmin was begun
concomitantly with the epinephrine. The propranolol was dis-
solved in haff-normal saline and infused at the rate of 0.27 ml!
mm. In the fourth study, propranolol (1.43 g!kgImin) alone
was started 30 mm prior to beginning the potassium infusion
and was continued throughout the 4-hour study period. Two
subjects were restudied on a fifth occasion to evaluate what role
increased plasma insulin concentration following epinephnne-
induced hyperglycemia might play in the improvement in potas-
sium tolerance. In this study, epinephrine infusion (0.05 pgI
kgmin) was begun 30 mm prior to potassium as described in
study two. But, 5 mm prior to starting the epinephrine, linear
somatostatin (provided by Drs. R. Guillemin and J. Rivier, Salk
Institute, San Diego, California) was begun at the rate of 500 g!
hr to inhibit insulin secretion. Simultaneously with somato-
statin, an infusion of crystalline procine insulin (Eli Lily Co.,
Indianapolis, Indiana) was begun at the rate of 0.07 mUIkgmin
designed to replace basal insulin levels. Blood pressure, heart
rate, and electrocardiogram were monitored at intervals of 15 to
30 mm throughout each study.
Following at least three baseline determinations, blood sam-
ples were drawn at intervals of 15 to 30 mm throughout the
study and analyzed for potassium, sodium, glucose, insulin,
creatinine, epinephrine, norepinephrine, and bicarbonate con-
centrations and venous pH. A total of 400 ml of blood was
drawn per study, and this was replaced quantitatively with
normal saline throughout the study. Studies were performed 2
to 3 weeks apart to allow time to replenish red blood cell losses.
Urine samples were collected at 30-mm intervals during the
study and were analyzed for potassium, sodium, and creatinine.
Analytical determinations. Potassium and sodium concentra-
tions in plasma and urine were determined by flame spectropho-
tometry (flame photometer, model 143, Instrumentation Labo-
ratory, Lexington, Massachusetts) using lithium as the internal
standard. Plasma and urine creatinine concentrations were
determined by the method of Jaffe adapted to the autoanalyzer
[2]. Methods for the determination of plasma insulin have
previously been published [1]. Plasma epinephrine and norepi-
nephrine concentrations were determined by radioenzymatic
assay [13] in the laboratory of Dr. R. Hendler. Plasma glucose
concentration was determined by the glucose oxidase method
(glucose analyzer, Beckman Instrument, Fullerton, California).
Calculations. Clearances of creatinine, potassium, and sodi-
um were calculated according to the formula C = UVIP, where
U is the urinary concentration, V is the urine volume, and P is
the plasma concentration. We have previously shown that basal
urinary potassium excretion remains constant for up to 6 hours
in subjects infused with saline [141. To calculate the amount of
infused potassium excreted for any given time period, we
subtracted the mean basal potassium excretion rate in each
subject from the mean rate of potassium excretion during that
time period, and multiplied it by the time, in minutes. The
sodium excretion was calculated in a similar manner to that for
net potassium excretion.
The amount of infused potassium retained within the body
during the 4-hour study was calculated by subtracting the net
amount of potassium excreted during the 4 hours from the total
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amount of potassium administered. The amount of potassium
that was disposed of by extrarenal mechanisms was calculated
from the difference between the expected rise in plasma potassi-
um concentration (amount of potassium retained ÷ extracellu-
tar fluid volume) and the actual rise in the plasma potassium
concentration, multiplied by the extracellular fluid volume. In
this calculation, the assumption is made that ECF volume
remains constant at 20% of body wt.
Potassium tolerance was expressed as the integrated rise in
plasma potassium concentration, which was calculated as the
area under the curve plotting the rise in plasma potassium with
time. This expression of area uses all the data points obtained
during potassium loading rather than relying on a single plasma
potassium value. This area was calculated using the trapezoidal
rule approximation and was carried out by the subroutine
QAOIAS of the Harwell Subroutine Library of the Yale Univer-
sity IBM 370/158 computer. Extrarenal potassium tolerance
was quantitated by dividing the incremental area in plasma
potassium concentration (mEqlliter x mm) by the amount of
potassium retained (mEq). This value, expressed as minutes per
liter, gives a more specific measure of the amount of the
potassium load that disappeared from the ECF by extrarenal
disposal.
All values are expressed as the means SEM. Comparisons
of groups was performed with Student's paired t test [15].
Results
Vital signs. During the potassium chloride infusion alone, no
change in heart rate or blood pressure was observed. When
epinephnne was infused with potassium chloride, a variable
increase in heart rate (10 to 15 beats/mm) and a widening of
pulse pressure (10 to 20 mm Hg) occurred. Subjectively, most
subjects reported feelings of tremulousness and a pounding
heart beat, which was most marked at the beginning of the
epinephrine infusion and subsided after the first 60 mm. When
propranolol was added to the potassium chloride and epineph-
rifle infusion, no change in heart rate or pulse pressure was
observed, and no subjective sensations were reported by any
volunteer. When propranolol was infused alone, heart rate
decreased by 5 to 10 beats/mm without change in blood
pressure.
Potassium infusion. During the potassium chloride infusion
alone, baseline plasma potassium concentration (3.77 0.11
mEq/liter) rose progressively, reaching a maximum of 0.83
0.09 mEq/liter above baseline at 2 hours (Fig. 1). The potassium
chloride infusion was stopped after 2 hours, and thereafter the
plasma potassium concentration progressively declined, reach-
ing a value of 0.38 0.14 mEq/liter above basal at the end of the
4-hour study. The incremental area in plasma potassium during
the 240-mm time period was 126.5 16.2 mEq/liter mm (Fig.
2, top panel). Urinary potassium excretion increased signifi-
cantly from a mean baseline rate of 37 12 iEq/min to a mean
maximum rate of 184 15 Eq/min (Fig. 3) without a change in
creatinine clearance (Table 1). Of the infused potassium, 47
4% was excreted during the 4-hour study period (Fig. 4). Mean
urinary potassium excretion in the three subjects serving as
time controls was 61 23 mEq/min at the onset of study and
was unchanged after 6 hours (60 18 mEq/min).
Of the infused potassium that was retained within the body at
the end of the 4-hour study period, 24.8 1.2 mEq was
translocated out of the ECF by extrarenal mechanisms (Fig. 5),
0
0 30 0 90 120 160 180 210 240
Time, mm
Fig. 1. Time course of change in the plasma potassium concentration
(PyJ with potassium chloride alone (O—O), epinephrine plus potassi-
um chloride (i---), epinephrine plus propranolol plus potassium
chloride (D—'-—D), and propranolol plus potassium chloride (IS).
All values represent the mean SEM. P values refer to the control
group (*P < 0.05, < 0.01, tP < 0.001).
and this represented 82 5% of the retained potassium and 43
5% of the total potassium dose administered. The increment
in plasma potassium concentration expressed per amount of
potassium retained during the 0 to 240 mm was 4.2 0.5 min/
liter.
Venous pH (7.34 0.01) and bicarbonate concentration (24
1 mEq/liter) did not change following potassium chloride or in
any of the subsequent studies.
Epinephrine plus potassium. When epinephrine was infused
alone for 30 mm preceding the potassium chloride infusion, the
plasma potassium concentration fell from 3.66 0.10 to 3.05
0.06 mEq/liter. This later value was taken as the baseline
plasma potassium concentration from which the increment in
potassium concentration following potassium chloride infusion
was calculated. When the potassium chloride infusion was
begun after epinephrine pretreatment, the rise in plasma potas-
sium concentration was significantly less than it was with
potassium chloride infusion alone during the first 120 mm, P <
0.001 (Fig. 1). During the last 2 hours following potassium
chloride administration, the increase in plasma potassium con-
centration above baseline was similar to that observed with the
potassium chloride infusion alone. The incremental area in
plasma potassium concentration was slightly, although not
significantly, less than it was with potassium chloride infusion
alone during the 0 to 240 mm interval (Fig. 2, top panel).
The mean baseline urinary excretion of potassium (UKV) was
37 7 pEq/min, which was similar to that with potassium
infusion alone (Fig. 3). Following the epinephrine infusion (Fig.
3), UKV decreased to a mean value of 21 3 Eq/min, which
was significantly below the basal excretion rate (P < 0.001) and
was markedly less than the maximum excretion rate in study
one when potassium chloride was infused alone (P < 0.001).
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Fig. 2. Top Panel Integrated rise in plasma potassium concentration
(PK) expressed as the incremental area in plasma potassium concentra-
tion above baseline (mEq/liter x mm) following potassium chloride
alone, epinephrine plus potassium chloride, epinephrine plus proprano-
lol plus potassium chloride, and propranolol plus potassium chloride.
All values represent the mean SEM. P values refer to the control
group. Bottom panel Incremental area in plasma potassium concentra-
tion (mEqiliter x mm) per amount of potassium retained (mEq) with
potassium chloride, epinephrine plus potassium chloride, epinephrine
plus propranolol plus potassium chloride, and propranolol plus potassi-
um chloride. All values represent the mean SEM. P values refer to the
control group. (* <0.02, < 0.005).
The total amount of potassium excreted over the 4-hour study
period fell below that expected if the basal rate of potassium
excretion continued unchanged, P < 0.001 (Fig. 4). Creatinine
clearance was not significantly altered by epinephrine (Table 1).
Despite a decrease in urinary potassium excretion to values
below the basal rate of excretion, the plasma potassium concen-
tration actually rose less than it did with potassium chloride
alone because the extrarenal disposal of potassium increased by
greater than twofold compared to that with potassium chloride
alone, P < 0.001 (Fig. 5). The incremental area in plasma
potassium concentration per amount potassium retained was
significantly less than it was with potassium chloride alone
during the 0 to 240 mm, P < 0.005 (Fig. 2, bottom panel).
Propranolol plus epinephrine plus potassium chloride. When
propranolol was infused with epinephrine for 30 mm preceding
potassium chloride infusion, the plasma potassium concentra-
tion did not change significantly from the baseline value of 3.69
0.11 mEq/liter. When the potassium chloride infusion was
begun 30 mm after starting epinephrine and propranolol, the
rise in plasma potassium concentration above baseline was
significantly greater than it was with potassium chloride infu-
sion alone during the first 120 mm (P < 0.01) (Fig. 1) and tended
to remain higher for the duration of the study. The incremental
area in plasma potassium (Fig. 2, top panel) was also greater
with propranolol plus epinephrine compared with potassium
chloride alone (P < 0.02).
UKV (Fig. 3) was slightly less than it was with potassium
chloride alone during the first 60 mm but was not different
thereafter. The percentage of the potassium dose excreted (Fig.
4) during the 4-hour study, 31 6%, was significantly less than
it was with potassium chloride alone (P < 0.02). Creatinine
clearance (Table 1) was unaffected by the addition of proprano-
lol.
The total amount of potassium that was translocated out of
the extracellular fluid (Fig. 5) was similar to potassium chloride
alone and significantly less than it was with epinephrine plus
potassium chloride (P < 0.001). When the incremental area in
potassium is factored by the amount of potassium retained (Fig.
2, bottom panel), it can be seen that propranolol completely
blocked the enhancing effect of epinephrine on extrarenal
potassium tolerance; the incremental rise per amount of potas-
sium retained was actually higher than it was with potassium
chloride (P < 0.02).
Propranolol plus potassium chloride. When propranolol was
infused alone for 30 mm preceding the potassium chloride
infusion, the plasma potassium concentration did not change
significantly from baseline, 3.75 0.13 mEq/liter. Following
the potassium chloride infusion, the rise in plasma potassium
concentration (Fig. 1) and also the incremental area in plasma
potassium concentration (Fig. 2, top panel) were slightly,
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Fig. 3. Time course of change in urinary potassium excretion (UKV)
with potassium chloride alone (0—0), epinephrine plus potassium
chloride (i---), epinephrine plus propranolol plus potassium chloride
(J........D), and propranolol plus potassium chloride (• . I). All
values represent the mean SEM. P values refer to the control group.(* < 0.001, **p < 0.02).Inc
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Table 1. Creatinine clearance, baseline sodium excretion, and net sodium excretion following potassium chloride alone, and potassium chloride
given with combinations of epinephrine and propranolola
KCI infusion
Epinephrine + KCI
infusion
Epinephrine +
propranolol + KCI Propranolol + KCI
Basal Post infusionBasal Post infusion Basal Post infusion Basal Post infusion
Creatinine clearance, mI/mm
Sodium excretion, mEqimin
Net sodium excretion, mEq
152 162
92 229C
— 18
161 163
69 132C
— 8"
147 140
60 189C
— 18
162 149
120 269C
— 12
a Values are the means SEM.
b p < 0.02, compared with all other groups.
C This is the maximum increase in UNaV.
Fig. 4. Percentage of the administered potassium dose excreted with
potassium chloride alone, epinephrine plus potassium chloride, epi-
nephrine plus propranolol plus potassium chloride, and propranolol
plus potassium chloride. All values represent the mean SEM. P values
refer to the control group (**P < 0.02, p < 0.001).
although not significantly, higher than they were with potassi-
um chloride alone.
The mean baseline UKV, 57 16 p.Eq/min, was similar to the
three previous studies. Following the infusion of potassium
chloride, the increase in potassium excretion was higher than it
was with potassium chloride alone at all time points (Fig. 3),
and the percentage of the potassium toad excreted (Fig. 4) was
greater than it was with potassium chloride alone (P < 0.02).
Creatinine clearance was unaffected by propranolol (Table 1).
The amount of potassium disposed of by extrarenal mecha-
nisms, 11.9 2.9 mEq, was significantly less than it was with
potassium chloride alone, P < 0.001 (Fig. 5). Likewise, the
incremental area in potassium per amount of potassium retained
Fig. 5. Absolute amount of potassium transloca ted out of the ECF by
extrarenal mechanisms with potassium chloride, epinephrine plus po-
tassium chloride, epinephrine plus propranolol plus potassium chlo-
ride, and propranolol plus potassium chloride. All values represent the
mean SEM. P values refer to the potassium chloride group (*P <
0.001).
(Fig. 2, bottom panel) during the 4-hour study period was
significantly greater than it was with potassium chloride alone
(P < 0.005).
Sodium. Baseline plasma sodium concentrations were similar
in all four studies and were unaffected by any of the experimen-
tal maneuvers.
The baseline urinary sodium excretion rates (UNaV) were
also similar in all four studies. Following the infusion of
potassium chloride, UNaV rose significantly in all four groups
(Table 1), but the rise with epinephrine plus potassium chloride
was significantly less (P < 0.02) compared with each of the
other three groups.
Glucose. Fasting plasma glucose concentrations were similar
in the potassium chloride (85 2 mg/dl), the potassium chloride
plus epinephrine (84 3 mg/dl), the potassium chloride plus
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Epinephrine or epinephrine + propranolol or propranolol
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Fig. 6. Top panel Time course of change in the plasma glucose
concentration following potassium chloride alone (0 0), epi-
nephrine plus potassium chloride (A---A), epinephrine plus propranolol
plus potassium chloride (0——D), and propranolol plus potassium
chloride (I S). All values represent the mean SEM. The plasma
glucose concentrations during the epinephrine and epinephrine-pro-
pranolol infusions were significantly higher (P < 0.001) than they were
with potassium chloride alone during all time intervals. Bottom Panel
Time course of change in the plasma insulin concentration following
potassium chloride alone (0 0), epinephrine plus potassium
chloride (A---L), epinephrine plus propranolol plus potassium chloride
(EJ—'—LO, propranolol plus potassium chloride (• •). All values
represent the mean SEM. P values refer to the potassium chloride
group (*P < 0.02, < 0.001).
epinephrine and propranolol (80 3 mg/dl), and the potassium
chloride plus propranolol (88 3 mg/dl) studies. The plasma
glucose concentration remained unchanged during the potassi-
um chloride infusion (Fig. 6, top panel). When epinephrine was
infused along with potassium chloride, an immediate and signif-
icant rise in the plasma glucose concentration occurred and the
hyperglycemia persisted throughout the duration of the study
(Fig. 6, top). When propranolol was infused with epinephrine,
the rise in plasma glucose concentration was blunted but
significant hyperglycemia still remained. Propranolol alone had
no effect on the plasma glucose concentration.
Insulin. Baseline plasma insulin concentration was similar in
all four studies (Fig. 6, bottom). No change in the plasma insulin
concentration occurred following potassium chloride infusion
alone. Infusion of epinephrine with potassium chloride resulted
KCI KCI
500
400
Time, rn/n
I I I I
60 120 180 240
Fig. 7. Change in plasma epinephrine and plasma norepinephrine
concentrations during the infusion of potassium chloride alone.
in a 15 to 20 p.U/ml increase in the plasma insulin concentration
(Fig. 6, bottom), which correlated temporally with the rise in
plasma glucose concentration (Fig. 6, top). The rise in plasma
insulin concentration persisted throughout the 4-hour study
period. When propranolol was administered along with epi-
nephrine, an initial small decline in the plasma insulin concen-
tration was observed (Fig. 6, bottom), but thereafter the plasma
insulin values were not significantly different from those with
potassium chloride alone. Propranolol infusion alone had no
effect on the plasma insulin concentration.
Plasma epinephrine and norepinephrine concentrations.
Baseline plasma epinephrine and norepinephrine concentra-
tions during the potassium chloride infusion study alone were
16 8 and 420 107 pg/ml, respectively (Fig. 7). Following
infusion of potassium chloride, no significant change in either
plasma catecholamine concentration was observed.
Somatostatin-insulin plus epinephrine plus potassium. When
somatostatin was infused with epinephrine to inhibit insulin
secretion and an exogenous insulin infusion was given to
maintain basal plasma insulin levels, the mean plasma insulin
concentration during the 4-hour study period was maintained at
the fasting level (Table 2). In both patients, the incremental area
in plasma potassium concentration was slightly higher (19%)
than when epinephrine was infused alone. Because the percent-
age of the administered potassium dose that was excreted was
similar in the epinephrine and the epinephrine plus somato-
statin-insulin protocols, the incremental plasma potassium area
factored by the amount of potassium retained was also slightly
higher (14%) when insulin secretion was inhibited with somato-
statin.
Discussion
Previous studies in animals, using the infusion of pharmaco-
logic doses of both epinephrine and potassium, have demon-
strated that epinephrine ameliorates the rise in plasma potassi-
um concentration and decreases the incidence of fatal cardiac
arrythmias [9, 10]. The present study extends these earlier
observations to man and documents that physiologic elevations
in plasma epinephrine levels, similar to those observed in
stress, are capable of blunting the rise in plasma potassium
concentration following the infusion of small amounts of potas-
sium. When potassium was administered following pretreat-
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Table 2. Summary of potassium data during the infusion of somatostatin-insulin plus epinephrine plus potassium in two patients
Patient I Patient 2
EPI
EPI + SRIF
+ Insulin EPI
EPI + SRIF
+ Insulin
Basal PK, mEqiliter
PK postepinephrine, mEq/literb
Maximum PK, mEq/liter
Maximum change in rise of PK, mEqlliter
Incremental area in PK, mEqiliter >< mm
K dose excreted, %
K dose retained, %
Amount of K translocated into cells, mEq
Retained K translocated into cells, %
Incremental PK area per
K retained, mm/liter
Basal plasma glucose, mg/dl
Maximum rise in glucose, mg/dl
Basal plasma insulin, .U/ml
Mean plasma insulin,C iU/mF
3.65
3.14
3.86
0.72
114.6
—7
107
49.5
87
1.88
86
172
15
32
—
3.77
3.27
4.17
0.90
136.4
12
112
48.0
84
2.12
91
190
17
19
3.70
3.20
3.85
0.65
82.6
—16
116
53.6
94
1.46
85
176
16
35
3.89
3.25
4.03
0.78
98.8
—18
118
50.0
85
1.68
86
214
15
14
C Abbreviations are: EPI, epinephrine; SRIF, somatostatin and insulin.b Plasma potassium concentration 30 mm following epinephrine infusion and immediately prior to starting potassium chloride infusion.
C Mean plasma insulin concentration during the 4-hr study period starting with the infusion of potassium chloride.
ment with epinephrine, the rise in plasma potassium concentra-
tion was significantly attenuated. This blunted rise in plasma
potassium concentration is even more striking when changes in
urinary potassium excretion are taken into account. Following
potassium chloride infusion alone, 47% of the infused potassi-
um was excreted. This value agrees well with those previously
reported under similar experimental conditions [21. When epi-
nephrine was infused along with potassium chloride, urinary
potassium excretion was markedly inhibited and actually fell
below baseline values (P < 0.001). When the rise in plasma
potassium concentration is factored by the amount of infused
potassium retained within the body, a greater than twofold
increase in the amount of potassium disposed of by extrarenal
mechanisms was observed (Fig. 2, bottom). The importance of
this protective effect of epinephrine on extrarenal potassium
tolerance would assume particular significance during condi-
tions of stress. Under such circumstances, a state of net
catabolism exists. This would be expected to result in a net
influx of potassium from the intracellular to the extracellular
compartment at a time when both insulin secretion [171 and
insulin action [18] are significantly impaired. Because stress is
known to stimulate epinephrine release, the increased circulat-
ing levels of this hormone could exert a protective effect against
the development of hyperkalemia.
The mechanism by which epinephrine augments extrarenal
disposal of potassium is most likely related to stimulation of
beta adrenergic receptors because the augmentation can be
blocked by propranolol. Recent studies have demonstrated the
presence of beta receptors on both liver and skeletal muscle
cells [19, 20], the two major tissues responsible for potassium
uptake in man. Because epinephnne infusion was associated
with a 15 to 20-p.U/ml rise in plasma insulin concentration and
because hyperinsulinemia can enhance cellular uptake of potas-
sium [211, we performed additional studies in two patients to
define the contribution of insulin to the improvement in potassi-
um tolerance observed following epinephrine. In these studies,
somatostatin was used to inhibit endogenous insulin secretion,
and an exogenous insulin infusion was concomitantly given to
replace basal insulin levels. When this was done, the incremen-
tal area in plasma potassium concentration per amount of
potassium retained (14%) was slightly greater than it was when
epinephrine was administered alone (Table 2). But the actual
values for the incremental rise in plasma potassium concentra-
tion per amount of potassium retained in the two subjects (2.12
and 1.68 mm/liter) were still markedly less than were the mean
values when potassium chloride was infused alone (4.2 0.5
mm/liter). Thus, although insulin probably contributes to the
enhanced extrarenal uptake of potassium following epineph-
rifle, it does not play the predominant role. The plasma potassi-
um response during the 30-mm epinephrine infusion preceding
the administration of potassium also suggests that increased
insulin secretion does not account for the improved potassium
tolerance observed with epinephrine. During this period, the
plasma potassium concentration declined by 0.42 0.05 mEq/
liter at 15 mm and by 0.61 0.06 mEq/liter at 30 mm. Yet, the
plasma insulin concentration remained unchanged at 15 mm and
was only slightly elevated at 30 mm. In three of six subjects, no
rise in plasma insulin concentration occurred during the first 30
mm after epinephrine infusion, whereas a significant decline in
plasma potassium concentration occurred in all.
An indirect effect of epinephrine, mediated via stimulation of
aldosterone secretion, cannot be excluded by the present study.
This would seem unlikely, however, because the effect of
epinephrine on plasma potassium is immediate, whereas the
increase in plasma aldosterone does not occur until 30 to 60 mm
[221 following epinephrine administration, and the onset of
action of aldosterone in stimulating potassium transport is
delayed by 60 to 120 mm [23].
The ability of epinephnne to enhance potassium tolerance
cannot be attributed to enhanced renal excretion of potassium
because UKV decreased markedly following epinephrine infu-
sion. It is unlikely that this decrease in UKV can be explained
by changes in plasma glucose or insulin concentration. In the
absence of glycosuria, we are unaware of any direct effect of
90 DeFronzo et a!
hyperglycemia on renal tubular transport of potassium. Al-
though insulin has been reported to depress urinary potassium
excretion [24], when insulin secretion was inhibited with soma-
tostatin, the decrease in urinary potassium excretion following
epinephrine was similar to that observed when epinephrine was
infused without somatostatin. These results suggest that the
antikaluretic effect of epinephrine is independent of changes in
insulin concentration. This antikaliuretic effect cannot be attrib-
uted to a fall in the peritubular capillary potassium concentra-
tion perfusing the distal nephron or to a fall in the filtered load
of potassium, because the plasma potassium concentration
increased following potassium chloride infusion and the GFR
was unchanged. Epinephrine is known to decrease renal plasma
flow [25]. Therefore, it is possible that the total amount of
potassium presented to the distal potassium secretory sites
actually diminished, leading to a decrease in the potassium
excretion rate, even though the plasma potassium concentra-
tion rose.
Lastly, what role the lower plasma potassium concentration
may have played in the failure to observe a rise in UKV
following epinephrine should be considered. Baseline plasma
potassium concentration, 3.66 mEq/liter, fell to 3.05 after 30
mm of epinephrine infusion. At this time the potassium chloride
infusion was begun and by 120 mm the plasma potassium had
risen by 0.6 mEq/liter, that is, it had returned to the basal
preepinephrine infusion value. At this time, UKV had actually
decreased significantly (P < 0.001) to below the baseline UKV.
Thus, the lower UKV compared with the potassium chloride
group alone could be in large part explicable by the lower
plasma potassium concentration. But, the fact that UKV actual-
ly fell below basal levels suggests the possibility that epineph-
rifle may inhibit, either directly or indirectly, renal tubular
potassium secretion. Because the current investigation was not
designed to directly examine the effect of epinephrine on renal
potassium excretion, further studies are needed to delineate this
possibility.
The infusion of propranolol in conjunction with epinephrine
reversed both the renal (Fig. 3) and extrarenal effects (Fig. 2) of
epinephrine on potassium metabolism, indicating that the effect
of epinephrine is in large part mediated by stimulation of beta
adrenergic receptors. The extrarenal disposal of potassium was
actually less during potassium chloride plus propranolol than it
was with potassium chloride alone. Two possible explanations
could account for this observation. First, it is possible that
propranolol not only blocked the effect of the infused epineph-
rine, but also had an additional action by inhibiting the effect of
basal epinephrine levels. This is supported by the studies in
which propranolol alone was infused with potassium chloride.
Second, part of the deterioration in potassium tolerance follow-
ing combined epinephrine-propranolol infusion could be the
result of an unopposed alpha effect of epinephrine. Additional
studies with alpha agonists and antagonists are in progress to
answer this question.
The deleterious effects of propranolol on extrarenal potassi-
um tolerance could be explained in several ways. First, it is
possible that hyperkalemia stimulates epinephrine release from
the adrenal medulla and that propranolol, by blocking this
stimulatory effect of potassium could have a detrimental effect
on potassium tolerance. Measurements of circulating catechol-
amines during the potassium chloride infusion, however, failed
to demonstrate a significant increase in circulating plasma
epinephrine levels. This does not, however, exclude the possi-
bility that an increase in plasma potassium concentration could
activate sympathetic nerve fibers innervating muscle and liver
cells with local uptake and degradation of epinephrine without a
change in circulating plasma levels. Such local epinephrine
degradation has been shown to occur by Axelrod and Weinshil-
borm [26]. It is also possible that basal levels of epinephrine or
basal sympathetic nervous system activity are necessary to
dispose of an exogenous potassium load normally and that
propranolol, by inhibiting the effect of basal epinephrine or by
inhibiting basal sympathetic nervous system activity, leads to
impaired potassium tolerance. The decrease in the extrarenal
disposal of potassium (Fig. 5) when propranolol was infused
alone with potassium chloride suggests that this is probably the
explanation for the decrease in potassium tolerance following
beta blockade. Thus, propranolol not only blocks the effects of
exogenously infused epinephrine on cellular potassium uptake,
but also inhibits the effect of basal epinephrine levels. These
results are similar to the situation with insulin where inhibition
of basal insulin secretion by as little as 50% results in a marked
impairment in potassium tolerance [1].
The effects of propranolol on renal potassium handling are
also opposite to those of epinephrine. Propranolol reversed the
inhibitory effect of epinephrine on potassium excretion and,
when infused alone with potassium chloride, led to a significant
increase in UKV (Figs. 3 and 4). These results suggest that,
even in the basal state, sympathetic nervous system activity
plays an important role in potassium homeostasis with beta
stimulation enhancing cellular potassium uptake and inhibiting
renal potassium excretion. Furthermore, both the renal and
extrarenal effects can be reversed by beta blockade.
The current data are in agreement with the recent findings of
Rosa et al [11]. These authors demonstrated an improvement in
potassium tolerance with epinephrine and an impairment in
potassium tolerance with beta blockade. In contrast to the
present investigation, urinary potassium excretion was not
enhanced with propranolol in that study, possibly due to the
lower dose of the drug used. Similarly, the lower dose of
epinephrine used in that study could explain their finding of a
reduction but not a complete inhibition of urinary excretion of a
potassium load. In the current study, the increase in urinary
potassium excretion in response to potassium loading was
completely prevented with a higher dose of epinephrine, sug-
gesting a dose-related inhibitory effect of epinephrine on uri-
nary potassium excretion.
Summary. The present study documents that elevations of
circulating plasma epinephrine concentrations, similar to levels
observed in stress, ameliorate the rise in plasma potassium
concentration following a potassium chloride infusion. This
effect is the result of enhanced extrarenal disposal of potassium
and can be reversed by propranolol, indicating that epineph-
rifle's protective effect on potassium tolerance is in large part
mediated via stimulation of beta adrenergic receptors.
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